Who is sponsoring NCT06238752?

NCT06238752 is sponsored by Renmin Hospital of Wuhan University.

What drugs are being tested in NCT06238752?

Interventions in NCT06238752: Apatinib Combined With Tislelizumab and Chemotherapy.

What condition does NCT06238752 study?

NCT06238752 studies Advanced Gastric Adenocarcinoma.

Is NCT06238752 still recruiting?

NCT06238752 is currently completed. Last updated 2 February 2024.

Last reviewed 2024-02-02 · How we verify

NCT06238752: RENMIN-213

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC

Completed Phase 2 Last updated 2 February 2024

What this trial tests

Phase 2 trial testing Apatinib Combined With Tislelizumab and Chemotherapy in Advanced Gastric Adenocarcinoma in 33 participants. Completed in 1 January 2024.

Timeline

1 March 2021

Primary endpoint
1 March 2023

1 January 2024

Quick facts

Lead sponsor	Renmin Hospital of Wuhan University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 March 2021
Primary completion	1 March 2023
Estimated completion	1 January 2024
Sites	1 location across China

Drugs / interventions tested

Apatinib Combined With Tislelizumab and Chemotherapy — full drug profile →

Conditions studied

Advanced Gastric Adenocarcinoma — all drugs for Advanced Gastric Adenocarcinoma →

Sponsor

Renmin Hospital of Wuhan University

Who can join

18 and older, any sex, with Advanced Gastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this clinical study, investigators explore the efficacy and safety of a combination therapy regimen with antiangiogenic agent (apatinib), ICI (tislelizumab), and chemotherapy (capecitabine+ Oxaliplatin, XELOX) as first-line treatment for HER2-negative, advanced G/GEJ cancer patients with signet ring cell carcinoma or peritoneal metastasis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report.
Zhao J, Li X, Sun X, Xiao R, et al · · 2025 · cited 4× · PMID 40040691 · DOI 10.3389/fimmu.2025.1533700
Progress of immune checkpoint inhibitors in gastric cancer.
Wan JY, Zhang D, Wu XH, Yang H, et al · · 2025 · cited 1× · PMID 40837753 · DOI 10.4251/wjgo.v17.i8.109613
Immune checkpoint blockade in cancer: current insights and future horizons.
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, et al · · 2026 · PMID 41483376 · DOI 10.1007/s12672-025-04361-7
Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative Review
Poniewierska-Baran A, Sobolak K, Niedźwiedzka-Rystwej P, Plewa P, et al · · 2024

Verify or expand the search:

Other recruiting trials for Advanced Gastric Adenocarcinoma

Currently open trials in the same condition.

NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
NCT06203600 — Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · Phase 2, PHASE3 · recruiting
NCT05677490 — mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg · Phase 3 · recruiting
NCT05041153 — Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma · EARLY_PHASE1 · recruiting
NCT04209686 — Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma · Phase 2 · active not recruiting

Other Renmin Hospital of Wuhan University trials

Trials by the same sponsor.

NCT07587294 — Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patien · NA · not yet recruiting
NCT07269509 — Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhi · NA · not yet recruiting
NCT07151560 — Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in · Phase 2 · not yet recruiting
NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
NCT06614985 — The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06238752 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Renmin Hospital of Wuhan University
Last refreshed: 2 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06238752.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing